市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Erasca, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.0
| 分析师共识 | -1.5 |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.00 |
|
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 11.69% |
| 机构持股比例 | 84.38% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 30 Sep 2025 | 22,729,436 |
| Logos Global Management Lp | 30 Sep 2025 | 15,150,000 |
| Arch Venture Management, Llc | 30 Sep 2025 | 11,055,554 |
| Affinity Asset Advisors, Llc | 30 Sep 2025 | 4,285,787 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 11.00 (Piper Sandler, 10.44%) | 购买 |
| 11.00 (HC Wainwright & Co., 10.44%) | 购买 | |
| 中 | 8.00 (-19.68%) | |
| 低 | 5.00 (Mizuho, -49.80%) | 购买 |
| 5.00 (Guggenheim, -49.80%) | 购买 | |
| 平均值 | 8.00 (-19.68%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 5.75 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Piper Sandler | 16 Jan 2026 | 11.00 (10.44%) | 购买 | 9.62 |
| 07 Jan 2026 | 5.00 (-49.80%) | 购买 | 5.17 | |
| HC Wainwright & Co. | 13 Jan 2026 | 11.00 (10.44%) | 购买 | 7.51 |
| Mizuho | 09 Dec 2025 | 5.00 (-49.80%) | 购买 | 3.30 |
| Guggenheim | 14 Nov 2025 | 5.00 (-49.80%) | 购买 | 2.58 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合